Last reviewed · How we verify

NK510 : allogeneic genetic modified NK

Base Therapeutics (Shanghai) Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic nameNK510 : allogeneic genetic modified NK
SponsorBase Therapeutics (Shanghai) Co., Ltd.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: